HC Wainwright Reaffirms Buy Rating for Atossa Therapeutics (NASDAQ:ATOS)

HC Wainwright restated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $7.00 price target on the stock.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets lifted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Trading Down 3.3 %

Shares of ATOS opened at $0.72 on Wednesday. The stock has a market cap of $90.16 million, a P/E ratio of -3.26 and a beta of 1.20. The company has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.16. Atossa Therapeutics has a 12-month low of $0.70 and a 12-month high of $2.31.

Hedge Funds Weigh In On Atossa Therapeutics

A number of institutional investors have recently modified their holdings of ATOS. Gallagher Capital Advisors LLC acquired a new position in shares of Atossa Therapeutics in the fourth quarter valued at approximately $25,000. Millennium Management LLC acquired a new position in shares of Atossa Therapeutics in the fourth quarter valued at approximately $28,000. Intech Investment Management LLC acquired a new position in shares of Atossa Therapeutics in the third quarter valued at approximately $29,000. Two Sigma Advisers LP raised its position in shares of Atossa Therapeutics by 214.1% in the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock valued at $40,000 after buying an additional 28,900 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after buying an additional 16,853 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.